Liver disease in the elderly

Gastroenterology Clinics of North America

Volumn 30, Issue 2, 2001, Pages 547-563

  Regev, Arie ^b   Schiff, Eugene R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BENOXAPROFEN; ISONIAZID;

AGED; AGING; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; LIVER REGENERATION; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; REVIEW; VIRUS HEPATITIS;

EID: 0034978783     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(05)70195-3     Document Type: Article

References (116)

1. Age greater than 50 years is not a contraindication for liver donation
2. Liver transplantation from elderly donors
3. Incidence of parenchymal liver disease in Denmark, 1981 to 1985: Analysis of hospitalization registry data
4. Epidemiology of hepatitis C
5. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
6. Report from the Pitt-UNOS Liver Transplant: Registry
7. Prevalence of chronic liver disease in the general population of Northern Italy
8. Aging is associated with reduced liver regeneration and diminished thymidine kinase mRNA content and enzyme activity in the rat
9. Hepatocellular carcinoma in the elderly: Results of surgical and nonsurgical management
10. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis
11. Hepatitis C virus infection in the elderly
12. Orthotopic liver transplantation in patients over 60 years old
13. The prognosis of elderly subjects with esophageal varices
14. Donor factors influencing organ transplant prognosis
15. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age
16. Alterations in human immune response to the hepatitis B vaccine among the elderly
17. Deaths and hospitalization from chronic liver disease and Cirrhosis - United States, 1980-1989
18. Prediction of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver Cirrhosis
19. Adverse drug reactions
20. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver
21. Liver transplantation in patients beyond age 60
22. Safe use of hepatic allografts from donors older than 70 years
23. Use of interferon for the treatment of chronic hepatitis C in the elderly
24. Kinetics of hepatic amino-nitrogen conversion in ageing man
25. Anti-hepatitis C virus in the elderly: A seroepidemiological study in a home for the aged
26. Increasing age - An important adverse prognostic factor in hepatitis A virus infection
27. Changing epidemiology and clinical aspects of hepatitis A
28. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use
29. Risk factors and prognosis in primary biliary cirrhosis
30. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability
31. Does donor age exclude liver grafting?
32. Outcome of patients undergoing orthotopic liver transplantation with elderly donors (over 60 years)
33. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: Therapeutic considerations (Part I)
34. Sensitivity to triazolam in the elderly
35. Drug disposition in old age
36. Hepatocellular carcinoma in the elderly: Results of surgical management
37. Primary biliary cirrhosis in elderly females
38. Donor age and outcome of liver transplantation
39. Interferon therapy for patients more than 60 years of age with chronic hepatitis C
40. Chronic liver disease in the extremely elderly of 80 years or more: Clinical characteristics, prognosis and patient survival analysis
41. An exploratory population-based case-control study of primary biliary cirrhosis
42. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
43. Drugs and the ageing liver
44. Parenchymal liver disease in the elderly
45. Effect of age on liver function
46. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
47. High carrier rate after hepatitis B virus infection in the elderly
48. Isoniazid related hepatitis
49. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area
50. Fulminant hepatic failure
51. Is primary biliary cirrhosis a different disease in the elderly?
52. Early primary biliary cirrhosis: Just delayed or different?
53. Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes
54. Value of profiling liver function in the elderly
55. Liver disease in the elderly
56. Liver transplantation: An overview
57. Galactose elimination capacity and liver volume in aging man
58. Effect of donor age and sex on the outcome of liver transplantation
59. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
60. Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis
61. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England
62. Hepatitis C virus infection and related chronic liver disease in a resident elderly population: The Silea study
63. The use of marginal donors for liver transplantation: A retrospective study of 365 liver donors
64. Halothane anaesthesia and liver damage
65. Autoimmune hepatitis in older patients
66. Prescribing for the elderly: Part I. Sensitivity of the elderly to adverse drug reaction
67. Endoscopic injection sclerotherapy for esophageal varices in the elderly
68. Liver disease in the elderly
69. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C
70. Orthotopic liver transplantation in patients 60 years of age and older
71. Glucose-6-phosphatase and age: Biochemical and histological studies
72. Hepatocellular carcinoma in the elderly: Results of surgical and non surgical management
73. Aging and the liver
74. Natural history of liver fibrosis progression in patients with chronic hepatitis C
75. Randomised trial of interferon α2b plus ribavirin for 48 weeks of for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
76. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
77. Injection sclerotherapy for esophageal varices in the elderly
78. Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949-94: Trend analysis
79. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
80. Similar outcomes, morbidity, and mortality for orthotopic liver transplantation between the very elderly and the young
81. Age,related changes on parameters of experimentally-induced liver injury and regeneration
82. Hepatocyte fine structure during maturation and senescence
83. Aging in the third millenium
84. Liver transplantation in the United States from 1987-1998: Update results from Pitt-UNOS Liver Transplantation Registry
85. + availability in F344 rats
86. Chronic active hepatitis in the elderly
87. Factors predictive of the response to interferon in patients with chronic hepatitis C
88. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines
89. Age and cytochrome P450-linked metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions
90. Age and cohort effects in primary liver cancer
91. Liver transplantation in patients over sixty years of age
92. Fatal cholestatic jaundice in elderly patients taking benoxaprofen
93. Age changes in size and number of mitochondria of human hepatic cells
94. Effect of age on liver function with particular reference to bromsulphthalein excretion
95. Effect of ageing on rat liver regeneration after partial hepatectomy
96. Treatment of hepatitis C virus in elderly persons with interferon α
97. Clinical pharmacokinetics of antidepressants in the elderly: Therapeutic implications
98. The use of older donor livers for hepatic transplantation
99. Effect of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes
100. Graft function and outcome of older (> or = 60 years) donor livers
101. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies
102. Hepatitis C: Global prevalence
103. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
104. Serious hepatitis A: An analysis of patients hospitalized during an urban epidemic in the United States
105. Age-related changes in liver size and hepatic blood flow: The influence on drug metabolism in the elderly
106. The association of age and frailty with paracetamol conjugation in man
107. The effect of age upon liver volume and apparent liver blood flow in healthy man
108. Hepatic drug clearance: The effect of age using indocyanine green as a model compound
109. The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver
110. The association of age with the activity of alcohol dehydrogenase in human liver
111. Epidemiology and long term prognosis off hepatitis C virus infection in Japan
112. The association of age with aspirin esterase activity in human liver
113. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients
114. Age and liver transplantation: A report of the liver transplantation database
115. Total and functional hepatic blood flow decrease in parallel with ageing